Replies to post #109570 on Avid Bioservices Inc (CDMO)

[cjgaddy]

R622, “Chimera” is actually Patrick Crutcher, who revealed his mindset clearly in these 2 BVals posts:

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
By Pcrutch iHub-BVals #146826 8-9-12 5:53PM (post removed)
“…I think it's criminal PPHM is still giving their drug to patients.”
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78383525

By PCrutch iHub-BVals #146814 8-9-12
“Well I am expecting triple failure of all their trials this fall (NSCLC 1st & 2nd line, Pancreatic). I will be smiling then.”
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78376986

= = = = = = = = = = = = = = =8-27-12
At that time, I decided to let him know his makeover didn’t go unnoticed by me:

8-27-12/SA - Patrick, tell me again why you dropped your name and went “anonymous” with this PPHM hatchet job, and switched the date from Aug24 to Aug27 when you copy/pasted the original one it over from your esteemed “Chimera Research Group” website?
=> There’s not an honest bone in your body, Patrick Crutcher. You know it yourself, and now a ton of other people do too.
I know I’ll never believe another word you write – ABOUT ANYTHING.

= = = = = =
THIS ONE: 8-27-12: “More Downside Expected In Peregrine Pharmaceuticals”
By: ((anonymous))
“There appears to be significant reason to be cautious with this name. . .” etc etc etc
http://seekingalpha.com/article/828911-more-downside-expected-in-peregrine-pharmaceuticals (PPHM 8-27-12 $2.20=>$1.87)
DISCLOSURE: “I am short PPHM.”

COPY OF: 8-24-12 “PPHM – More downside expected in Peregrine Pharmaceuticals”
AUGUST 24, 2012, Chimera Research Group
“There appears to be significant reason to be cautious with this name. . .” etc etc etc
http://www.chimeraresearchgroup.com/2012/08/quick-analysis-on-peregrine-pharmaceuticals
DISCLOSURE: “No position currently, but considering Sept. $2.50 puts.”
.
.
= = = = = = = = = = = = = = =
As opposed to:

1-11-11: “Peregrine Seems Poised For Growth In 2011”
by Patrick Crutcher
http://biomedreports.com/2011011162299/peregrine-poised-for-growth-in-2011.html
Back then you said you were LONG on PPHM, and you wrote,
“BAVITUXIMAB is an extremely interesting molecule which has created a lot of buzz over the past 2 years; not just in oncology but also as a potent anti-viral. . . PPHM entered into an ATM with MLV to the tune of $75 million. WE VIEW THIS DEAL POSITIVELY, since it allows them to raise capital as share price increases and it is not selling them at a discount to a fund. They have one of the best un-partnered pipelines amongst small-cap biotechs and WE ARE EXCITED ABOUT THE POTENTIAL OVER AT PEREGRINE.”